Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 16.21 USD -4.37%
Market Cap: 1.8B USD

Novocure Ltd
Investor Relations

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space.

The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

Show more
Loading

Earnings Calls

2024 Q4
Jan 23, 2025
Show Transcript
Previous
Next
Horizon Bancorp Displays Strong Loan Growth and Optimistic 2025 Outlook
2024 Q4
Jan 23, 2025

In Horizon Bancorp's fourth quarter, total loans grew by $123 million, achieving a 10% annualized growth, driven largely by commercial lending. The company anticipates continued growth, projecting a mid-single-digit increase in 2025, while absorbing a $100 million decline in lower-yielding auto loans. Margin performance also strengthened, with a net interest margin of 2.97%, expected to improve to about 3.15-3.20% by year-end. Horizon aims to keep noninterest expenses steady and targets a tax rate in the mid-teens, indicating strong operational efficiency and long-term value for shareholders.

Show Full Analysis

Management

Mr. William F. Doyle
Executive Chairman
No Bio Available
Ms. Ashley Cordova
Chief Financial Officer
No Bio Available
Mr. Frank Leonard
Executive VP & President of Novocure Oncology
No Bio Available
Mr. Mukund Paravasthu
Chief Operating Officer
No Bio Available
Ms. Ingrid Goldberg
VP of Investor Relations
No Bio Available
Mr. Michael Puri
Chief Human Resources Officer
No Bio Available
Mr. Uri Weinberg M.D., Ph.D.
Chief Innovation Officer
No Bio Available
Mr. Piet Hinoul M.D., Ph.D.
Senior VP, Head of Global Medical Affairs & Interim Head of Medical
No Bio Available
Dr. Nicolas Leupin M.B.A., M.D., Ph.D.
Chief Medical Officer
No Bio Available

Contacts

Address
Saint Helier
No. 4 The Forum, Grenville Street
Contacts
+441534756700.0
www.novocure.com